{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"30"}],"title":"No Complete Response"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"36"}],"units":"Participants"}],"description":"CRR is defined as Complete Response Rate. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"Romidepsin 8 mg/m\\^2/Lenalidomide 10 mg","id":"OG000","title":"Dose Level -1"},{"description":"Romidepsin 8 mg/m\\^2/Lenalidomide 15 mg","id":"OG001","title":"Dose Level 1"},{"description":"Romidepsin 8 mg/m\\^2/Lenalidomide 25 mg","id":"OG002","title":"Dose Level 2"},{"description":"Romidepsin 10 mg/m\\^2/Lenalidomide 25 mg","id":"OG003","title":"Dose Level 3"},{"description":"Romidepsin 14 mg/m\\^2/Lenalidomide 25 mg","id":"OG004","title":"Dose Level 4"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"No participants treated on Dose Level -1","reportingStatus":"POSTED","timeFrame":"1 year","title":"Complete Response Rate/CRR","type":"SECONDARY","unitOfMeasure":"Participants"}